Kura Oncology (KURA) Fundamental Analysis: Revenue, Earnings & Valuation

7.11 / 10

Outperform

Fundamentally, Kura earns an Outperform rating with a 7.1/10 quality score. Strong interest coverage (35.1x) and favorable PB‑ROE (+0.07) support the view, while revenue growth exceeds 25% YoY. Inventory turnover and cost‑of‑sales ratios are modest, and asset‑MV is positive, offset by a slight revenue‑MV lag.

Analysis Checks(9/10)

Revenue-MV

Value-1.96

Score1/3

Weight14.33%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value25.24

Score2/3

Weight0.40%

1M Return0.13%

Inventory turnover ratio

Value0.28

Score2/3

Weight-3.29%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value20.73

Score3/3

Weight5.36%

1M Return1.67%

PB-ROE

Value0.07

Score3/3

Weight36.35%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.76

Score3/3

Weight2.52%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.35%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value25.24

Score2/3

Weight0.16%

1M Return0.05%

Cost of sales ratio (%)

Value0.08

Score2/3

Weight-3.16%

1M Return-1.13%

Asset-MV

Value-0.55

Score3/3

Weight50.67%

1M Return11.61%

Is KURA undervalued or overvalued?

KURA scores 7.11/10 on fundamentals and holds a Discounted valuation at present. Backed by its -94.82% ROE, -412.95% net margin, -2.64 P/E ratio, 4.23 P/B ratio, and -57.43% earnings growth, these metrics solidify its Outperform investment rating.